Melatonin and Ramelteon for the treatment of delirium: A systematic review and meta-analysis.

To assess the efficacy of melatonin and melatonergic agonist for the treatment of delirium in hospitalized patients. Embase, MEDLINE, PsycINFO, PubMed, CENTRAL, Cochrane Database of Systematic Reviews, TRIP Medical Database, ClinicalTrials.gov and Google were searched from inception to October 2022. Randomized controlled trials (RCT) and observational studies with any type of comparator evaluating melatonin or melatonergic agonist (ramelteon) enrolling any populations (ICU, surgery, geriatric) were included. Two reviewers independently selected and extracted data using the Cochrane risk of bias tools (RoB2 and ROBINSI). Out of the 650 screened publications, three RCTs and six observational studies were included (n = 1211). All three RCTs compared melatonin to placebo, as the majority of observational studies compared melatonin or ramelteon to antipsychotics. Two RCTs reported the duration of delirium and a meta-analysis provided a statistical difference between melatonin and placebo (-1.72 days, 95% CI -2.66 to -0.77, p = 0.0004). Five observational studies reported the duration of delirium but only one reported a statistical reduction in the duration of delirium. Although melatonin and ramelteon may be effective treatments for delirium, particularly to shorten the duration of delirium and to limit the use of rescue medication, current data is limited in number and in its quality. Clinicians should wait until higher quality data from ongoing RCTs are available before prescribing melatonin to delirious patients. Copyright © 2023 Elsevier Inc. All rights reserved.

Citation

Johannie Beaucage-Charron, Justine Rinfret, Richard Coveney, David Williamson. Melatonin and Ramelteon for the treatment of delirium: A systematic review and meta-analysis. Journal of psychosomatic research. 2023 Jul;170:111345

Mesh Tags

Substances

PMID: 37150157

search → result